NO753230L - - Google Patents
Info
- Publication number
- NO753230L NO753230L NO753230A NO753230A NO753230L NO 753230 L NO753230 L NO 753230L NO 753230 A NO753230 A NO 753230A NO 753230 A NO753230 A NO 753230A NO 753230 L NO753230 L NO 753230L
- Authority
- NO
- Norway
- Prior art keywords
- units
- mol
- active substance
- weight
- molding compound
- Prior art date
Links
- 239000013543 active substance Substances 0.000 claims description 49
- 229920001296 polysiloxane Polymers 0.000 claims description 43
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 40
- 238000000465 moulding Methods 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 22
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 20
- 229910052697 platinum Inorganic materials 0.000 claims description 17
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 16
- -1 polydimethylsiloxane Polymers 0.000 claims description 14
- 239000012876 carrier material Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000012907 medicinal substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 22
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000969 carrier Substances 0.000 description 17
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229960001652 norethindrone acetate Drugs 0.000 description 12
- 229920001971 elastomer Polymers 0.000 description 11
- 239000000806 elastomer Substances 0.000 description 11
- 229960004400 levonorgestrel Drugs 0.000 description 11
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 9
- 229920002379 silicone rubber Polymers 0.000 description 9
- 238000004073 vulcanization Methods 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 239000004753 textile Substances 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000003058 platinum compounds Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 4
- 229960001390 mestranol Drugs 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940053934 norethindrone Drugs 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 239000004945 silicone rubber Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 229910002621 H2PtCl6 Inorganic materials 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 125000005375 organosiloxane group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000208734 Pisonia aculeata Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- IVFILROKUQKCPB-UHFFFAOYSA-N carbonyl dichloride;platinum Chemical compound [Pt].ClC(Cl)=O IVFILROKUQKCPB-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229950006690 dimethisterone Drugs 0.000 description 1
- 229920005645 diorganopolysiloxane polymer Polymers 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 239000012778 molding material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
- 229950011191 norgesterone Drugs 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920006136 organohydrogenpolysiloxane Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FLGJKPPXEKYCBY-AKCFYGDASA-N quingestanol acetate Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@H]1CC2)C)(OC(=O)C)C#C)C=C1C=C2OC1CCCC1 FLGJKPPXEKYCBY-AKCFYGDASA-N 0.000 description 1
- 229950009172 quingestanol acetate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- QFJIELFEXWAVLU-UHFFFAOYSA-H tetrachloroplatinum(2+) dichloride Chemical compound Cl[Pt](Cl)(Cl)(Cl)(Cl)Cl QFJIELFEXWAVLU-UHFFFAOYSA-H 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19742445971 DE2445971A1 (de) | 1974-09-24 | 1974-09-24 | Arzneimittelwirkstofftraeger ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO753230L true NO753230L (en, 2012) | 1976-03-25 |
Family
ID=5926793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO753230A NO753230L (en, 2012) | 1974-09-24 | 1975-09-23 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4012497A (en, 2012) |
| JP (1) | JPS5161618A (en, 2012) |
| AT (1) | AT347588B (en, 2012) |
| AU (1) | AU498204B2 (en, 2012) |
| BE (1) | BE833762A (en, 2012) |
| BG (1) | BG27880A3 (en, 2012) |
| CA (1) | CA1049408A (en, 2012) |
| CH (1) | CH624580A5 (en, 2012) |
| DD (1) | DD122197A5 (en, 2012) |
| DE (1) | DE2445971A1 (en, 2012) |
| DK (1) | DK143384C (en, 2012) |
| EG (1) | EG11859A (en, 2012) |
| ES (1) | ES441203A1 (en, 2012) |
| FI (1) | FI58871C (en, 2012) |
| FR (1) | FR2285895A1 (en, 2012) |
| GB (1) | GB1521505A (en, 2012) |
| HU (1) | HU175675B (en, 2012) |
| IE (1) | IE41717B1 (en, 2012) |
| IL (1) | IL48100A (en, 2012) |
| IN (1) | IN142359B (en, 2012) |
| IT (1) | IT1042731B (en, 2012) |
| NL (1) | NL7511244A (en, 2012) |
| NO (1) | NO753230L (en, 2012) |
| PL (1) | PL105375B1 (en, 2012) |
| SE (1) | SE7510658L (en, 2012) |
| SU (1) | SU605547A3 (en, 2012) |
| ZA (1) | ZA756082B (en, 2012) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
| US4219016A (en) * | 1978-12-07 | 1980-08-26 | The Procter & Gamble Company | Vaginal contraceptive |
| US4191741A (en) * | 1978-09-22 | 1980-03-04 | Eli Lilly And Company | Removable drug implant |
| US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| US4200090A (en) * | 1979-01-15 | 1980-04-29 | The Procter & Gamble Company | Vaginal contraceptive and method of using |
| US4264576A (en) * | 1979-06-28 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
| US4479795A (en) * | 1979-06-29 | 1984-10-30 | The Procter & Gamble Company | Antimicrobial polymer compositions |
| US4343788A (en) * | 1979-06-29 | 1982-08-10 | The Procter & Gamble Company | Antimicrobial polymer compositions |
| US4264578A (en) * | 1979-07-16 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
| US4264575A (en) * | 1979-07-16 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
| US4264577A (en) * | 1979-08-03 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
| US4341728A (en) * | 1979-12-20 | 1982-07-27 | The Population Council, Inc. | Method for making an IUD with shrinking of a medicated attachment onto a support |
| US4304226A (en) * | 1980-03-03 | 1981-12-08 | The Procter & Gamble Company | Vaginal contraceptive |
| GB2079158B (en) * | 1980-06-09 | 1985-01-09 | Ahi Operations Ltd | Intra-vaginal devices |
| DE3040978A1 (de) * | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Vaginalring |
| EP0076068A3 (en) * | 1981-09-25 | 1985-05-15 | Beecham Group Plc | Intramammary veterinary compositions and method for their use |
| NZ200564A (en) * | 1982-05-10 | 1987-03-06 | Ahi Operations Ltd | Device for slowly releasing chemicals into body cavities of animals |
| US4435180A (en) | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
| US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
| FR2560768A1 (fr) * | 1984-03-07 | 1985-09-13 | Crb Virbac Sa | Dispositif a liberation programmee |
| WO1985004798A1 (en) * | 1984-04-19 | 1985-11-07 | University Of Queensland | Contraceptive methods and delivery systems therefore |
| US4673565A (en) * | 1985-05-03 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Pharmaceutical compositions containing hollow fine tubular drug delivery systems |
| NZ217844A (en) * | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
| US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
| US5238679A (en) * | 1987-02-26 | 1993-08-24 | Rhone-Poulenc Chimie | Diorganopolysiloxane dosage forms for the controlled release of iodine values |
| FR2611734B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition elastomere silicone polycondensation contenant de l'iode pour le traitement des eaux |
| FR2611735B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition elastomere silicone polyaddition contenant de l'iode pour le traitement de l'eau |
| FR2611733B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition a base de gomme diorganopolysiloxane contenant de l'iode pour le traitement des eaux |
| US4879304A (en) * | 1987-05-01 | 1989-11-07 | Angelini Pharmaceuticals Ltd. | Ophthalmic compositions and process for preparing |
| HU197519B (en) * | 1987-06-22 | 1989-04-28 | Biogal Gyogyszergyar | Process for producing medicine form capable for penetrating through epidermis and suitable for intaking the agent through epidermis by kinetics of zero-grade |
| DE3727180A1 (de) * | 1987-08-14 | 1989-02-23 | Wacker Chemie Gmbh | Waessrige silicondispersionen |
| US5019601A (en) * | 1987-12-29 | 1991-05-28 | Cuno, Incorporated | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
| US5019378A (en) * | 1987-12-29 | 1991-05-28 | Cuno, Incorporated | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
| US4867968A (en) * | 1987-12-29 | 1989-09-19 | Florida-Kansas Health Care, Inc. | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
| US4879294A (en) * | 1988-01-28 | 1989-11-07 | Angelini Pharmaceuticals Ltd. | Opthalmic composition |
| US4906475A (en) * | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
| JP2590358B2 (ja) * | 1988-03-01 | 1997-03-12 | 正雄 五十嵐 | 子宮内膜症治療用の子宮内又は膣内投与製剤 |
| DE3838815A1 (de) * | 1988-11-17 | 1990-05-23 | Hoechst Ag | Verfahren zum herstellen eines intravaginalen applikationssystems |
| GB2252497B (en) * | 1991-02-04 | 1995-01-18 | Elsimar Metzker Coutinho | Pharmaceutical composition |
| US5620499A (en) * | 1992-12-14 | 1997-04-15 | Farley; James J. | Chemical dispensing device and method |
| US5505963A (en) * | 1993-04-07 | 1996-04-09 | Schwartz Pharma Ag | Slow release pharmaceutical preparation |
| MXPA01002609A (es) * | 1998-09-10 | 2002-04-08 | Sumitomo Pharma | Preparacion de farmaco de liberacion sostenida a largo plazo. |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| JP2006500115A (ja) | 2000-11-16 | 2006-01-05 | マイクロスフエリツクス・エル・エル・シー | 密封小線源治療用の可撓性および／または弾性シードまたはストランド |
| IL157771A0 (en) * | 2001-03-27 | 2004-03-28 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| WO2003080018A1 (en) * | 2002-03-27 | 2003-10-02 | Galen (Chemicals) Limited | Intravaginal matrix drug delivery devices |
| ATE445393T1 (de) * | 2003-04-24 | 2009-10-15 | Jagotec Ag | Tablette mit gefärbtem kern |
| WO2006026844A1 (en) * | 2004-09-09 | 2006-03-16 | Biolab Sanus Farmacêutica Ltda. | Hormone delayed release composition on the basis of polyorganosiloxanes or ethylene vinyl acetate resp. process for its manufacture |
| US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| EA015304B1 (ru) | 2006-08-03 | 2011-06-30 | Нитек Фарма Аг | Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением |
| CA2725578A1 (en) * | 2008-04-24 | 2009-10-29 | Evestra, Inc. | Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
| US20100040671A1 (en) * | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
| US8420153B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
| US8419793B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
| EP2391369A1 (en) * | 2009-01-26 | 2011-12-07 | Nitec Pharma AG | Delayed-release glucocorticoid treatment of asthma |
| US20110270168A1 (en) * | 2010-05-03 | 2011-11-03 | Izhar Halahmi | Releasing device for administering a bio-active agent |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| WO2015198104A1 (es) * | 2014-06-28 | 2015-12-30 | Laboratorios Andromaco S.A. | Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, útil para la prevención de parto prematuro |
| ES2756301T3 (es) | 2014-08-19 | 2020-04-27 | Univ California | Implantes de administración localizada de fármacos y métodos de uso de los mismos |
| US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| WO2025056040A1 (zh) * | 2023-09-13 | 2025-03-20 | 沈阳星华医药科技有限公司 | 药物组合物、载药棒芯、埋植剂及其制备方法、应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US3545439A (en) * | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
| US3920805A (en) * | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
-
1974
- 1974-09-24 DE DE19742445971 patent/DE2445971A1/de active Pending
-
1975
- 1975-08-27 IN IN1660/CAL/75A patent/IN142359B/en unknown
- 1975-09-10 EG EG540/75A patent/EG11859A/xx active
- 1975-09-12 IL IL48100A patent/IL48100A/xx unknown
- 1975-09-15 BG BG030981A patent/BG27880A3/xx unknown
- 1975-09-18 IE IE2049/75A patent/IE41717B1/en unknown
- 1975-09-22 AU AU85064/75A patent/AU498204B2/en not_active Expired
- 1975-09-22 DD DD188480A patent/DD122197A5/xx unknown
- 1975-09-22 AT AT724275A patent/AT347588B/de not_active IP Right Cessation
- 1975-09-23 ES ES441203A patent/ES441203A1/es not_active Expired
- 1975-09-23 NO NO753230A patent/NO753230L/no unknown
- 1975-09-23 CH CH1229875A patent/CH624580A5/de not_active IP Right Cessation
- 1975-09-23 FI FI752660A patent/FI58871C/fi not_active IP Right Cessation
- 1975-09-23 HU HU75SCHE537A patent/HU175675B/hu unknown
- 1975-09-23 GB GB38945/75A patent/GB1521505A/en not_active Expired
- 1975-09-23 IT IT27536/75A patent/IT1042731B/it active
- 1975-09-23 SE SE7510658A patent/SE7510658L/xx unknown
- 1975-09-23 US US05/616,001 patent/US4012497A/en not_active Expired - Lifetime
- 1975-09-23 SU SU752174604A patent/SU605547A3/ru active
- 1975-09-24 PL PL1975183556A patent/PL105375B1/pl unknown
- 1975-09-24 DK DK428175A patent/DK143384C/da active
- 1975-09-24 ZA ZA00756082A patent/ZA756082B/xx unknown
- 1975-09-24 BE BE160326A patent/BE833762A/xx unknown
- 1975-09-24 FR FR7529205A patent/FR2285895A1/fr active Granted
- 1975-09-24 CA CA236,245A patent/CA1049408A/en not_active Expired
- 1975-09-24 NL NL7511244A patent/NL7511244A/xx not_active Application Discontinuation
- 1975-09-25 JP JP50115955A patent/JPS5161618A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO753230L (en, 2012) | ||
| US4230686A (en) | Drug excipient of silicone rubber | |
| US3887699A (en) | Biodegradable polymeric article for dispensing drugs | |
| US3991766A (en) | Controlled release of medicaments using polymers from glycolic acid | |
| US4155991A (en) | Vaginal ring | |
| KR101592615B1 (ko) | 자궁내 시스템 | |
| US4012496A (en) | Vaginal ring | |
| DE69003347T2 (de) | Elemente mit protrahierter Wirkstoffabgabe. | |
| JP2001524124A (ja) | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 | |
| JP2022091999A (ja) | 避妊具及び関連した器具 | |
| JP2025510716A (ja) | シリコーン材料、シリコーンチューブ、インプラント、医薬組成物、薬物放出量の測定方法 | |
| WO2014122563A1 (en) | An intra vaginal device, and a method of reducing the rate of diffusion of active ingredients in said intra vaginal device | |
| IE42324B1 (en) | Pharmaceutical preparations containing silicone rubber | |
| CN100423792C (zh) | 缓释型睾丸假体及其应用 | |
| CN113509448A (zh) | 一种可生物降解控释长效植入片及其制备方法 | |
| EP3968950A1 (en) | Controlled release device for oral cavity | |
| PL90082B1 (en, 2012) | ||
| JP2003221338A (ja) | 子宮腺筋症治療製剤 | |
| JPS63203610A (ja) | 複数成分からなるインプラント用の持効性医薬製剤 | |
| CN116726370A (zh) | 聚合物微针、微针片及递送系统、制备方法、应用 | |
| WO2025054598A2 (en) | Biodegradable subcutaneous implant for delivery of therapeutics in a controlled pulsatile or sustained manner | |
| CN115350159A (zh) | 一种用于长效降血糖生物降解皮下埋植棒及其制备方法 | |
| WO2006026844A1 (en) | Hormone delayed release composition on the basis of polyorganosiloxanes or ethylene vinyl acetate resp. process for its manufacture | |
| Nanjwade et al. | SILICON BASED DRUG DELIVERY SYSTEM | |
| Alashetty | Histopathological Changes At Subdermal Region Due To Subdermal Biodegradable Polymer Implant An Experimental Study |